Drugs Made Valuation
| DMAA Stock | 10.47 -0.02 -0.19% |
At this time, Drugs Made appears to be overvalued. Drugs Made In has a current Real Value of $8.77 per share. The current price of Drugs Made is $10.47. Our model computes the value of Drugs Made In from analyzing Drugs Made fundamentals such as Shares Owned By Insiders of 26.77 %, market capitalization of 350.92 M, and Short Ratio of 0.55 X as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Drugs Made's valuation include:
Overvalued
Today
Please note that Drugs Made's price fluctuation is Very Low at this time. Calculation of the real value of Drugs Made In is based on 3 months time horizon. Increasing Drugs Made's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Drugs Made is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Drugs Stock. However, Drugs Made's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.47 | Real 8.77 | Hype 10.47 | Naive 10.48 |
The real value of Drugs Stock, also known as its intrinsic value, is the underlying worth of Drugs Made In Company, which is reflected in its stock price. It is based on Drugs Made's financial performance, growth prospects, management team, or industry conditions.
Estimating the potential upside or downside of Drugs Made In helps investors to forecast how Drugs stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Drugs Made more accurately as.Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. Some money managers use Drugs Made's intrinsic value based on ongoing forecasts of Drugs Made's financial statements.
How Much Is Drugs Made Worth?
Drugs Made is a small-cap equity in Diversified Capital Markets, Financial Services, NASDAQ Composite categories. Valuation integrates earnings durability and capital efficiency. Defensive traits reduce macro sensitivity. Drugs Made is evaluated for diversification characteristics within systematic portfolio structures.
Methodology
Unless otherwise specified, financial data for Drugs Made In is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Drugs (USA Stocks:DMAA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
This report references public filings and market reference sources and institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain datasets may update with delay depending on source availability. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Drugs Made In may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Drugs Made Current Valuation Indicators
Valuation work on Drugs Made In becomes more reliable when investors compare several lenses at once, including market value, enterprise value. revenue scale, and expected cash-flow durability. The better valuation questions are comparative: what is the market paying for each dollar of revenue, profit, and asset base, and is that premium justified?
Popular Tools for Drugs Stock analysis
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |